Sodium-Glucose Transporter-2 Inhibition: An Important Advancement for Patients with Type 2 Diabetes and Chronic Kidney Disease, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the speakers will review SGLT2 inhibitors and present emerging data on SGLT2 inhibitors and the impact on patients with type 2 DM and CKD.

Xtalks Life Science Webinars

Nearly half of CKD is attributed to diabetes, and we haven’t seen novel effective therapies for diabetic kidney disease (DKD) since the current standard of care with renal angiotensin aldosterone (RAAS) blockade was established about 18 years ago…until recently.

Join Barbara S. Gillespie, MD, MMS, FASN, Vice President & Therapeutic Head of Nephrology, Covance; Peter A. McCullough, MD, Founder and current president, Cardio Renal Society of America; Katherine R. Tuttle, MD, Executive Director for Research, Providence Health Care (PHC) in a live webinar on Tuesday, April 7, 2020 at 11am EST (4pm BST/UK).

Covance and the Cardio Renal Society of America (CRSA) are pleased to present this third webinar as part of our Cardio Renal Series, co-hosted by Dr. Barbara Gillespie (Therapeutic Head of Nephrology, Covance) and Dr. Peter McCullough (cardiologist and President, CRSA). They will co-host Dr. Katherine Tuttle, an endocrinologist and nephrologist, who has served in leadership positions in both fields and has been involved in many related clinical trials. Dr. McCullough and Dr. Tuttle will share their perspectives on the exciting data emerging on SGLT2 inhibitors and the impact on patients with type 2 diabetes mellitus (DM) and chronic kidney disease (CKD). CKD is an under-recognized epidemic, with an estimated global prevalence of 850 million, which is nearly double the global prevalence of DM at 422 million. Nearly half of CKD is attributed to diabetes, and we haven’t seen novel effective therapies for diabetic kidney disease (DKD) since the current standard of care with renal angiotensin aldosterone (RAAS) blockade was established about 18 years ago…until recently.

The speakers will share a brief review of SGLT2 inhibitors mechanism of actions & clinical effects, recent trial results and considerations for ongoing trial designs given some gaps in evidence. Since trial results are most meaningful when they can impact patients’ lives, getting SGLT2-I medications into the hands of patients is critical. Therefore, our experts will also discuss the importance of dissemination and implementation of emerging data so we can ensure adaptation of these medications for real-world use.

For more information or to register for this event, visit Sodium-Glucose Transporter-2 Inhibition: An Important Advancement for Patients with Type 2 Diabetes and Chronic Kidney Disease.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website